grant

Targeting SEC61 complex to overcome resistance to immunotherapy in GBM

Organization NORTHWESTERN UNIVERSITYLocation CHICAGO, UNITED STATESPosted 1 Jan 2025Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY2026AntibodiesApoptosisApoptosis PathwayBrain NeoplasiaBrain NeoplasmsBrain TumorsCAR T cellsCAR modified T cellsCAR-TCAR-TsCancersCell BodyCell Communication and SignalingCell SignalingCell TherapyCell-Mediated Lympholytic CellsCellsCephalicClinical TrialsCompanionsComplexCranialCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesCytotoxic cellDataDevelopmentDrug KineticsERK 1ERK1ERK1 KinaseEncapsulatedEndoplasmic ReticulumErgastoplasmExtracellular Signal-Regulated Kinase 1FutureGEM modelGEMM modelGenesGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenetically Engineered MouseGenomicsGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaImaging ProceduresImaging TechnicsImaging TechniquesImmune PrecipitationImmune mediated therapyImmunoblot AnalysisImmunologically Directed TherapyImmunoprecipitationImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapeutic agentImmunotherapyIn VitroInterventionIntracellular Communication and SignalingInvestigationK lymphocyteKnock-outKnockoutMAP Kinase 3MAP kinaseMAPK3MAPK3 Mitogen-Activated Protein KinaseMAPK3 geneMalignant NeoplasmsMalignant TumorMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMediatingMembrane Protein GeneMembrane ProteinsMembrane-Associated ProteinsMiceMice MammalsMitogen-Activated Protein Kinase 3Mitogen-Activated Protein Kinase 3 GeneMitogen-Activated Protein KinasesModelingMolecularMonitorMurineMusMyeloid CellsNK CellsNatural Killer CellsNeuroglial NeoplasmNeuroglial TumorOutcomeP44ERK1PSTkinase p44mpkPathway interactionsPatientsPharmacokineticsPhase I StudyPhenotypePhosphorylationPlayProgrammed Cell DeathProtein PhosphorylationProteinsProteomicsRecombinant DNA TechnologyRecurrent diseaseRelapsed DiseaseResistanceRoleShort interfering RNASignal TransductionSignal Transduction SystemsSignalingSmall Interfering RNASolid NeoplasmSolid TumorSurface ProteinsSurvival AnalysesSurvival AnalysisSurvival RateT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyTestingTranslatingTreatment ProtocolsTreatment RegimenTreatment ScheduleTumor-associated macrophagesadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapybiological signal transductioncancer microenvironmentcell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycheck point blockadecheckpoint blockadechimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical applicabilityclinical applicationclinical efficacydesigndesigningdevelopmentaldisease prognosisdisease prognosticationfirst in manfirst-in-humangenetically engineeredgenetically engineered mouse modelgenetically engineered murine modelgenome scalegenome-widegenomewideglial-derived tumorglioblastoma multiformeglioma cell linehuman modelimmune check point blockadeimmune checkpoint blockadeimmune drugsimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune suppressive macrophagesimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunosuppressive activityimmunosuppressive functionimmunosuppressive macrophagesimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimmunotherapeuticsimmunotherapy agentimprovedin vivoinhibitorinnovateinnovationinnovativekiller T cellknock-downknockdownliposomal deliveryliposome deliverymalignancymembermodel of humanmouse modelmurine modelneoplasm/cancerneuroglia neoplasmneuroglia tumoroverexpressoverexpressionp44 MAPKpathwayphase 1 studypolypeptidepre-clinicalpreclinicalpressureresistance mechanismresistance to therapyresistantresistant mechanismresistant to therapyresponsesafety assessmentscreeningscreeningssiRNAsmall molecular inhibitorsmall molecule inhibitorsocial rolespongioblastoma multiformesuccesstherapeutic T-cell platformtherapeutic resistancetherapeutic targettherapy resistantthymus derived lymphocytetooltreatment resistancetumortumor immune microenvironmenttumor microenvironmenttumor-immune system interactionstumors in the brain
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Glioblastoma (GBM) is an incurable brain tumor with a median overall survival of less than 15 months. The recent
success of immunotherapy in extracranial malignancies has translated into trials for GBM. Despite its promise,

immunotherapy's clinical efficacy has yet to be shown for GBM. The resistance to immunotherapy in GBM is

multifactorial. To…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Targeting SEC61 complex to overcome resistance to immunotherapy in GBM — NORTHWESTERN UNIVERSITY | UNITED STATES | Jan 2 | Dev Procure